GlassScriptPhysician profile
Susan G Manella
NPI 1730129065
$2,523.82
in general payments reported to CMS, 2019-2025
29 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $230 · 2021: $435 · 2022: $331 · 2023: $431 · 2024: $455 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.91 | 2019-2025 | |
| Novo Nordisk INC | $356.81 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.33 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $275.28 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $160.71 | 2019-2021 | |
| Amgen INC. | $131.36 | 2019-2025 | Otezla, Repatha |
| Pfizer INC. | $129.45 | 2020-2025 | |
| Boston Scientific Corporation | $116.69 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $96.26 | 2019-2024 | Airsupra |
| Exact Sciences Corporation | $65.06 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $55.10 | 2022-2024 | Freestyle Libre |
| Amarin Pharma, INC. | $45.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $37.49 | 2022 | |
| Sanofi Pasteur INC. | $33.50 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $31.69 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $29.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.93 | 2025 | |
| Ibsa Pharma INC. | $23.50 | 2025 | Tirosint, Flector, Licart |
| Allergan, INC. | $23.50 | 2020 | |
| Idorsia Pharmaceuticals US INC | $23.12 | 2024 | Quviviq |
| Verity Pharmaceuticals INC. | $21.40 | 2025 | Tlando |
| Phathom Pharmaceuticals, INC. | $21.25 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $20.67 | 2021 | |
| Genentech USA, INC. | $18.15 | 2021 | |
| Phadia US INC. | $15.77 | 2022 | |
| Hologic Sales and Service, LLC | $15.15 | 2019 | |
| Gilead Sciences, INC. | $13.56 | 2019 | |
| Glaxosmithkline, LLC. | $13.28 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Manella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.